ClariTrial — AI Clinical Trial Intelligence

Explore/infectious disease antibiotic antiviral trials recruiting

Status

Phase

22 results for “infectious disease antibiotic antiviral trials recruiting”

Page 1 of 2

NCT06653569

Recruiting

Efficacy of Baloxavir Against Influenza in Hospitalized Patients: the INFLUENT Study (INpatients InFLUENza Treatment)

Phase 3Influenza Disease; Flu

Baloxavir MarboxilPlacebo

Dre Pauline Vetter484 participants1 site · SwitzerlandCompletes Apr 2027

CT.gov Full analysis →

NCT07261969

Recruiting

CRP and Patient Information Leaflets to Optimise Antibiotic Treatments for Adults With Respiratory Tract Infections in Primary Care in Kyrgyzstan

N/ARespiratory Tract Infection BacterialRespiratory Tract Infection ViralAMR

The C-reactive protein point-of-care test (CRP-POCT)Patient information leaflets

Rigshospitalet, Denmark1,050 participants2 sites · KyrgyzstanCompletes Mar 2026

CT.gov Full analysis →

NCT07013474

Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Phase 3COVID-19 Infection

ibuzatrelvirremdesivirplacebo for ibuzatrelvir+1 more

Pfizer300 participants117 sites · United States, Argentina, BelgiumCompletes Dec 2026

CT.gov Full analysis →

NCT06488300

Recruiting

Assessing Antiviral Treatments in Early Symptomatic RSV

Phase 2Respiratory Syncytial VirusRespiratory Syncytial Virus, Human

RibavirinMolnupiravirFavipiravir

University of Oxford1,000 participants2 sites · Laos, ThailandCompletes Jan 2027

CT.gov Full analysis →

NCT05892666

Recruiting

The Right Care, for the Right Patient, at the Right Time, by the Right Provider: A Value-based Comparison of the Management of Ambulatory Patients With Acute Health Concerns in walk-in Clinics, Primary Care Physician Practices and Emergency Departments

N/AAmbulatory CareEmergency Services, HospitalQuality of Care

On-site recruitment (information and consent) following a random sampling recruitment scheduleFirst phone call 1-3 days after the initial visitSecond phone call 8-14 days after the initial visit

Simon Berthelot4,000 participants7 sites · CanadaCompletes Dec 2024

CT.gov Full analysis →

NCT05164926

Recruiting

The Use of St. John's Wort Oil With Massage in the Perineum During Childbirth

N/APerineal Injury

perineal massage with St. John's Wort oil

Ankara City Hospital Bilkent60 participants1 site · Turkey (Türkiye)Completes Oct 2024

CT.gov Full analysis →

NCT05897099

Recruiting

Comprehensive HIV and Harm Prevention Via Telehealth

N/AHIV Infections

Comprehensive Tele-harm ReductionOff-site Linkage to HIV Prevention

University of Miami350 participants2 sites · United StatesCompletes Mar 2028

CT.gov Full analysis →

NCT05325008

Recruiting

A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients

Phase 3BK ViremiaKidney Transplant InfectionKidney Transplant Failure and Rejection

Immunosuppression reduction/modification + intravenous immunoglobulinImmunosuppression reduction/modification

The University of Queensland280 participants12 sites · AustraliaCompletes Aug 2027

CT.gov Full analysis →

NCT02735707

Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3Community-acquired Pneumonia, Influenza, COVID-19

CeftriaxoneMoxifloxacin or LevofloxacinPiperacillin-tazobactam+59 more

UMC Utrecht20,000 participants408 sites · United States, Australia, BelgiumCompletes Feb 2026

CT.gov Full analysis →

NCT05648448

Recruiting

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Phase 2InfluenzaInfluenza, Human

OseltamivirFavipiravirZanamivir+7 more

University of Oxford3,000 participants4 sites · Brazil, Laos, NepalCompletes Jan 2027

CT.gov Full analysis →

NCT06679140

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Phase 3COVID-19 SARS-CoV-2 Infection

ibuzatrelvirplacebo

Pfizer2,330 participants234 sites · United States, Argentina, BelgiumCompletes Oct 2027

CT.gov Full analysis →

NCT05814237

Recruiting

POS-ARI-ER Observational Study of Acute Respiratory Infections

N/AAcute Respiratory InfectionAcute Respiratory Tract Infection

Data collection

European Clinical Research Alliance for Infectious Diseases (ECRAID)11,750 participants23 sites · Belgium, Croatia, FranceCompletes Feb 2026

CT.gov Full analysis →

NCT05564598

Recruiting

CMV CTLs in Neonates With CMV Infection

Phase 2Congenital Cytomegaloviral (CMV) Disease

CMV Cytotoxic T-LymphocytesAnti-viral Therapy

New York Medical College23 participants4 sites · United StatesCompletes Oct 2027

CT.gov Full analysis →

NCT05421325

Recruiting

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

Phase 2Immune Deficiency

QBKPN SSINormal Saline Placebo

Qu Biologics Inc.72 participants1 site · CanadaCompletes Sep 2025

CT.gov Full analysis →

NCT05597735

Recruiting

Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease

Phase 3MonkeypoxMpox

TecovirimatPlacebo

ANRS, Emerging Infectious Diseases480 participants12 sites · Argentina, Brazil, SwitzerlandCompletes Sep 2025

CT.gov Full analysis →

1–15 of 22

Explore/infectious disease antibiotic antiviral trials recruiting

Status

Phase

22 results for “infectious disease antibiotic antiviral trials recruiting”

Page 1 of 2

NCT06653569

Recruiting

Efficacy of Baloxavir Against Influenza in Hospitalized Patients: the INFLUENT Study (INpatients InFLUENza Treatment)

Phase 3Influenza Disease; Flu

Baloxavir MarboxilPlacebo

Dre Pauline Vetter484 participants1 site · SwitzerlandCompletes Apr 2027

CT.gov Full analysis →

NCT07261969

Recruiting

CRP and Patient Information Leaflets to Optimise Antibiotic Treatments for Adults With Respiratory Tract Infections in Primary Care in Kyrgyzstan

N/ARespiratory Tract Infection BacterialRespiratory Tract Infection ViralAMR

The C-reactive protein point-of-care test (CRP-POCT)Patient information leaflets

Rigshospitalet, Denmark1,050 participants2 sites · KyrgyzstanCompletes Mar 2026

CT.gov Full analysis →

NCT07013474

Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Phase 3COVID-19 Infection

ibuzatrelvirremdesivirplacebo for ibuzatrelvir+1 more

Pfizer300 participants117 sites · United States, Argentina, BelgiumCompletes Dec 2026

CT.gov Full analysis →

NCT06488300

Recruiting

Assessing Antiviral Treatments in Early Symptomatic RSV

Phase 2Respiratory Syncytial VirusRespiratory Syncytial Virus, Human

RibavirinMolnupiravirFavipiravir

University of Oxford1,000 participants2 sites · Laos, ThailandCompletes Jan 2027

CT.gov Full analysis →

NCT05892666

Recruiting

N/AAmbulatory CareEmergency Services, HospitalQuality of Care

On-site recruitment (information and consent) following a random sampling recruitment scheduleFirst phone call 1-3 days after the initial visitSecond phone call 8-14 days after the initial visit

Simon Berthelot4,000 participants7 sites · CanadaCompletes Dec 2024

CT.gov Full analysis →

NCT05164926

Recruiting

The Use of St. John's Wort Oil With Massage in the Perineum During Childbirth

N/APerineal Injury

perineal massage with St. John's Wort oil

Ankara City Hospital Bilkent60 participants1 site · Turkey (Türkiye)Completes Oct 2024

CT.gov Full analysis →

NCT05897099

Recruiting

Comprehensive HIV and Harm Prevention Via Telehealth

N/AHIV Infections

Comprehensive Tele-harm ReductionOff-site Linkage to HIV Prevention

University of Miami350 participants2 sites · United StatesCompletes Mar 2028

CT.gov Full analysis →

NCT05325008

Recruiting

A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients

Phase 3BK ViremiaKidney Transplant InfectionKidney Transplant Failure and Rejection

Immunosuppression reduction/modification + intravenous immunoglobulinImmunosuppression reduction/modification

The University of Queensland280 participants12 sites · AustraliaCompletes Aug 2027

CT.gov Full analysis →

NCT02735707

Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3Community-acquired Pneumonia, Influenza, COVID-19

CeftriaxoneMoxifloxacin or LevofloxacinPiperacillin-tazobactam+59 more

UMC Utrecht20,000 participants408 sites · United States, Australia, BelgiumCompletes Feb 2026

CT.gov Full analysis →

NCT05648448

Recruiting

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Phase 2InfluenzaInfluenza, Human

OseltamivirFavipiravirZanamivir+7 more

University of Oxford3,000 participants4 sites · Brazil, Laos, NepalCompletes Jan 2027

CT.gov Full analysis →

NCT06679140

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Phase 3COVID-19 SARS-CoV-2 Infection

ibuzatrelvirplacebo

Pfizer2,330 participants234 sites · United States, Argentina, BelgiumCompletes Oct 2027

CT.gov Full analysis →

NCT05814237

Recruiting

POS-ARI-ER Observational Study of Acute Respiratory Infections

N/AAcute Respiratory InfectionAcute Respiratory Tract Infection

Data collection

European Clinical Research Alliance for Infectious Diseases (ECRAID)11,750 participants23 sites · Belgium, Croatia, FranceCompletes Feb 2026

CT.gov Full analysis →

NCT05564598

Recruiting

CMV CTLs in Neonates With CMV Infection

Phase 2Congenital Cytomegaloviral (CMV) Disease

CMV Cytotoxic T-LymphocytesAnti-viral Therapy

New York Medical College23 participants4 sites · United StatesCompletes Oct 2027

CT.gov Full analysis →

NCT05421325

Recruiting

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

Phase 2Immune Deficiency

QBKPN SSINormal Saline Placebo

Qu Biologics Inc.72 participants1 site · CanadaCompletes Sep 2025

CT.gov Full analysis →

NCT05597735

Recruiting

Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease

Phase 3MonkeypoxMpox

TecovirimatPlacebo

ANRS, Emerging Infectious Diseases480 participants12 sites · Argentina, Brazil, SwitzerlandCompletes Sep 2025

CT.gov Full analysis →

1–15 of 22